Inhibition of NHE1 Overcomes Temozolomide‐Resistance in Glioblastoma via ROS‐AKT/ERK Axis‐Mediated Autophagy Suppression
Journal of Biochemical and Molecular Toxicology · 2026
DOI: 10.1002/jbt.71110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Dan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Key Laboratory of Molecular Oncology, Tangshan People's Hospital, Hebei, China. Hauptthemen laut MEDLINE: Temozolomide, Sodium-Hydrogen Exchanger 1, Glioblastoma, Reactive Oxygen Species. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Planning Project Fund of Tangshan, the Key Discipline Fund of Tangshan, the Medical Science Research Program of Hebei Health Commission.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with temozolomide (TMZ) resistance being a major barrier to improved clinical outcomes. Dysregulated autophagy is closely associated with TMZ resistance in GBM, but the role of sodium/hydrogen exchanger 1 (NHE1)—a key regulator of intracellular pH homeostasis—in this process remains uncharacterized. We established a TMZ‐resistant GBM cell line (U251TR) and observed that U251TR cells displayed higher autophagic activity, increased reactive oxygen species (ROS) levels, and reduced apoptotic rates compared to parental U251 cells. Treatment with the NHE1‐specific inhibitor HOE‐642 dose‐dependently suppressed cell viability, inhibited NHE1 activity, reduced intracellular ROS production, and promoted apoptosis in U251TR cells, with a positive feedback loop identified between NHE1 and ROS. Mechanistically, HOE‐642 blocked autophagic initiation and flux primarily via the ROS‐AKT/ERK signaling axis, in which reduced ROS downregulated p‐AKT and p‐ERK1/2, where ERK exerted pro‐autophagic effects and AKT exerted anti‐autophagic effects. In vivo, combined HOE‐642 and TMZ treatment significantly reduced xenograft tumor volume and weight, inhibited autophagy, and activated apoptosis compared to TMZ monotherapy, without causing evident systemic toxicity. Our findings identify a novel NHE1‐ROS‐AKT/ERK‐autophagy regulatory axis in TMZ‐resistant GBM, validating NHE1 as a potential therapeutic target to enhance TMZ sensitivity by disrupting the autophagy‐apoptosis balance, and providing a new strategy for GBM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hebei Key Laboratory of Molecular Oncology, Tangshan People's Hospital, Hebei, China.
- Tangshan Key Laboratory of Cancer Prevention and Therapy, Tangshan People's Hospital, Hebei, China.
- The Cancer Institute, Tangshan People's Hospital, Hebei, China.
- Department of Neurosurgery, Tangshan People's Hospital, Tangshan, Hebei, China.
- Department of Pathology, Tangshan People's Hospital, Hebei, China.
- Department of Gastrointestinal Surgery, Tangshan People's Hospital, Hebei, China.
Förderung
- Science and Technology Planning Project Fund of Tangshan
- the Key Discipline Fund of Tangshan
- the Medical Science Research Program of Hebei Health Commission
Zitieren
APA
Li, D., Li, Y., Zheng, X., Wang, Z., Wang, Y., Zhang, J., Guo, J., Wang, L., Li, J., Liu, Y., & Li, Y. (2026). Inhibition of NHE1 Overcomes Temozolomide‐Resistance in Glioblastoma via ROS‐AKT/ERK Axis‐Mediated Autophagy Suppression. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.71110
Vancouver
Li D, Li Y, Zheng X, Wang Z, Wang Y, Zhang J, et al. Inhibition of NHE1 Overcomes Temozolomide‐Resistance in Glioblastoma via ROS‐AKT/ERK Axis‐Mediated Autophagy Suppression. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.71110
BibTeX
@article{Li2026,
author = {Li, Dan and Li, Yuhui and Zheng, Xuan and Wang, Zhuo and Wang, Yang and Zhang, Jun and Guo, Jianxiong and Wang, Lei and Li, Jingwu and Liu, Yongliang and Li, Yufeng},
title = {Inhibition of NHE1 Overcomes Temozolomide‐Resistance in Glioblastoma via ROS‐AKT/ERK Axis‐Mediated Autophagy Suppression},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
doi = {10.1002/jbt.71110}
}
EUVIMED